Ascentage Pharma’s 2025 Sales Soar 90% to US$82.1M Led by Olverembatinib
Ascentage Pharma’s 2025 product sales jumped 90% year-over-year to US$82.1 million, led by an 81% rise in Olverembatinib revenue to US$62.2 million and US$10.1 million from five months of Lisaftoclax sales. Nine global registrational Phase III trials are underway with four cleared by FDA and EMA, underpinning late-stage pipeline momentum as investor events are scheduled for March 26 to discuss clinical and commercial updates.
1. 2025 Financial Performance
The company’s product sales increased 90% to US$82.1 million in 2025, driven by Olverembatinib’s 81% revenue rise to US$62.2 million and US$10.1 million from five months of Lisaftoclax sales.
2. Commercial Milestones
Since January 2025, Olverembatinib has been covered on China’s National Reimbursement Drug List for all approved indications, boosting formulary presence to 825 direct-to-patient pharmacies and 355 hospitals by year-end. Lisaftoclax launched in late July, securing its position as the first Bcl-2 inhibitor approved for CLL/SLL in China.
3. Pipeline Advancements and Investor Events
Nine global Phase III registrational trials are in progress, with four cleared by FDA and EMA, targeting indications from Philadelphia chromosome-positive acute lymphoblastic leukemia to SDH-deficient gastrointestinal stromal tumor and acute myeloid leukemia. Bilingual investor webcasts are scheduled for March 26 to present detailed clinical and commercial updates.